Zydus Lifesciences Gets USFDA Approval for Heart Failure Drug
Jul 10, 2024 15:50
Zydus Lifesciences receives USFDA approval to market Sacubitril and Valsartan tablets for chronic heart failure treatment in adults.
Photograph: Courtesy Zydus.
New Delhi, Jul 10 (PTI) Zydus Lifesciences Ltd on Wednesday said it has received final approval from the US health regulator to market its generic Sacubitril and Valsartan tablets combination used to treat chronic heart failure in adults.
The approval by the US Food and Drug Administration (USFDA) is to market Sacubitril and Valsartan tablets of strengths 24 mg/26 mg, 49 mg/51 mg, and 97 mg/103 mg, Zydus Lifesciences said in a regulatory filing.
Sacubitril and Valsartan combination is used to treat chronic heart failure in adults to help reduce the risk of death and hospitalisation.
The drug will be manufactured at the group's formulation manufacturing facility in Moraiya, Ahmedabad, the company added.
DISCLAIMER - This article is from a syndicated feed. The original source is responsible for accuracy, views & content ownership. Views expressed may not reflect those of rediff.com India Limited.